Kelsen D P, Bains M, Cvitkovic E, Golbey R
Cancer Treat Rep. 1979 Nov-Dec;63(11-12):2019-21.
Vindesine, a new vinca alkaloid, has shown therapeutic activity in several human malignancies. A phase II study in 26 patients with squamous cell carcinoma of the esophagus was performed. Sixty percent of these patients had received prior chemotherapy. The starting dose was 3.0 mg/m2, which was escalated by 0.5 mg/m2 to a maximum of 4.5 mg/m2. Treatment was given once weekly for 7 weeks and every other week thereafter. Twenty-three patients were evaluable for response and toxicity. One complete remission (3 months), three partial remissions (5, 4, and 2+ months), and two minor responses (1.5 and 1 month) were seen. The major toxic effects were peripheral neuropathy, leukopenia, fever and myalgias, and alopecia. There was one drug-related death from leukopenia and sepsis. Vindesine has demonstrated therapeutic activity in esophageal carcinoma. Further studies with this agent are indicated.
长春地辛，一种新型长春花生物碱，已在多种人类恶性肿瘤中显示出治疗活性。对26例食管鳞状细胞癌患者进行了一项II期研究。这些患者中有60%曾接受过先前的化疗。起始剂量为3.0mg/m²，以0.5mg/m²递增至最大剂量4.5mg/m²。每周治疗1次，共7周，此后每隔一周治疗1次。23例患者可评估疗效和毒性。观察到1例完全缓解（3个月）、3例部分缓解（5、4和2+个月）以及2例轻度缓解（1.5和1个月）。主要毒性作用为周围神经病变、白细胞减少、发热和肌痛以及脱发。有1例因白细胞减少和败血症导致的与药物相关的死亡。长春地辛已在食管癌中显示出治疗活性。表明需要对该药物进行进一步研究。
